The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
Sign Up to like & getrecommendations! Published in 2017 at "Genetics in Medicine"
DOI: 10.1038/gim.2016.122
Abstract: Purpose:Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene. Migalastat, a pharmacological chaperone, binds to specific mutant forms of α-galactosidase A to restore lysosomal activity.Methods:A pharmacogenetic assay was… read more here.
Keywords: hek assay; validation pharmacogenetics; pharmacogenetics identification; fabry patients ... See more keywords